172 related articles for article (PubMed ID: 32034167)
1. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
Gorin JB; Malone DFG; Strunz B; Carlsson T; Aleman S; Björkström NK; Falconer K; Sandberg JK
Sci Rep; 2020 Feb; 10(1):2081. PubMed ID: 32034167
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
3. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
4. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Silva IPL; Batista AD; Lopes EP; Filgueira NA; Carvalho BT; Santos JC; Medeiros TB; Melo CRL; Lima MS; Lima K; Lacerda C; Lacerda HR
Rev Inst Med Trop Sao Paulo; 2021; 63():e6. PubMed ID: 33533809
[TBL] [Abstract][Full Text] [Related]
5. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
6. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents.
Terziroli Beretta-Piccoli B; Di Bartolomeo C; Deleonardi G; Grondona AG; Silvestri T; Tesei C; Melidona L; Cerny A; Mertens J; Semmo N; Semela D; Moradpour D; Mieli-Vergani G; Vergani D; Muratori L;
J Autoimmun; 2019 Aug; 102():89-95. PubMed ID: 31047768
[TBL] [Abstract][Full Text] [Related]
8. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Sasaki R; Meyer K; Moriyama M; Kato N; Yokosuka O; Ray RB; Aurora R; Ray R; Kanda T
J Med Virol; 2019 Mar; 91(3):411-418. PubMed ID: 30192392
[TBL] [Abstract][Full Text] [Related]
9. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
Iwasa M; Hara N; Miyachi H; Tanaka H; Takeo M; Fujita N; Kobayashi Y; Kojima Y; Kaito M; Takei Y
J Viral Hepat; 2009 Oct; 16(10):716-23. PubMed ID: 19302338
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Anthony DD; Sulkowski MS; Smeaton LM; Damjanovska S; Shive CL; Kowal CM; Cohen DE; Bhattacharya D; Alston-Smith BL; Balagopal A; Wyles DL
J Infect Dis; 2020 Sep; 222(8):1334-1344. PubMed ID: 32406487
[TBL] [Abstract][Full Text] [Related]
11. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
14. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.
Hengst J; Falk CS; Schlaphoff V; Deterding K; Manns MP; Cornberg M; Wedemeyer H
J Infect Dis; 2016 Dec; 214(12):1965-1974. PubMed ID: 27683821
[TBL] [Abstract][Full Text] [Related]
15. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
16. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C.
Weidner P; Boettche D; Zimmerer T; Burgermeister E; Teufel A; Ebert MPA; Antoni C
J Gastrointestin Liver Dis; 2018 Sep; 27(3):281-289. PubMed ID: 30240472
[TBL] [Abstract][Full Text] [Related]
17. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
18. The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C.
Papic N; Zidovec Lepej S; Gorenec L; Grgic I; Gasparov S; Filipec Kanizaj T; Vince A
PLoS One; 2018; 13(12):e0209481. PubMed ID: 30592759
[TBL] [Abstract][Full Text] [Related]
19. Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis.
Laursen TL; Sandahl TD; Kazankov K; Eriksen PL; Kristensen LH; Holmboe CH; Laursen AL; Vilstrup H; Grønbæk H
Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G151-G156. PubMed ID: 32597708
[No Abstract] [Full Text] [Related]
20. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.
Carlin AF; Aristizabal P; Song Q; Wang H; Paulson MS; Stamm LM; Schooley RT; Wyles DL
Hepatology; 2015 Oct; 62(4):1047-58. PubMed ID: 26147061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
